Health-Care Referrals from Direct-to-Consumer Genetic Testing
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: direct-to-consumer genetic testing (DTC-GT) provides personalized genetic risk information directly to consumers. Little is known about how and why consumers then communicate the results of this testing to health-care professionals. AIM: to query specialists in clinical genetics about their experience with individuals who consulted them after DTC-GT. METHODS: invitations to participate in a questionnaire were sent to three different groups of genetic professionals, totaling 4047 invitations, asking questions about individuals who consulted them after DTC-GT. For each case reported, respondents were asked to describe how the case was referred to them, the patient's rationale for DTC-GT, and the type of DTC-GT performed. Respondents were also queried about the consequences of the consultations in terms of additional testing ordered. The costs associated with each consultation were estimated. A clinical case series was compiled based upon clinician responses. RESULTS: the invitation resulted in 133 responses describing 22 cases of clinical interactions following DTC-GT. Most consultations (59.1%) were self-referred to genetics professionals, but 31.8% were physician referred. Among respondents, 52.3% deemed the DTC-GT to be "clinically useful." BRCA1/2 testing was considered clinically useful in 85.7% of cases; 35.7% of other tests were considered clinically useful. Subsequent referrals from genetics professionals to specialists and/or additional diagnostic testing were common, generating individual downstream costs estimated to range from $40 to $20,600. CONCLUSIONS: this clinical case series suggests that approximately half of clinical geneticists who saw patients after DTC-GT judged that testing was clinically useful, especially the BRCA1/2 testing. Further studies are needed in larger and more diverse populations to better understand the interactions between DTC-GT and the health-care system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An agenda for personalized medicine
Ng, P. C., Murray, S. S., Levy, S., & Venter, J. C. (2009) · Nature · doi:10.1038/461724a · Cited by 330 · cited 1×
“In recent years, numerous DTC-GT companies have emerged into this marketplace and considerable controversy has erupted over the accuracy and utility of such testing (Hunter et al ., 2008; Kraft and Hunter, 2009; McGuire and Burke, 2008; Evans and Green, 2009; Ng et al ., 2009).”
Cited by
Implementation and utilization of genetic testing in personalized medicine
Scott, S., Abul-Husn, N., Owusu Obeng, A., Sanderson, S., & Gottesman, O. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s48887 · Cited by 106
Legislation of direct-to-consumer genetic testing in Europe: a fragmented regulatory landscape
Kalokairinou, L., Howard, H. C., Slokenberga, S., Fisher, E., Flatscher-Thöni, M., Hartlev, M., van Hellemondt, R., Juškevičius, J., Kapelenska-Pregowska, J., Kováč, P., et al. (2018) · Journal of Community Genetics · doi:10.1007/s12687-017-0344-2 · Cited by 93
Enterprising or altruistic selves? Making up research subjects in genetics research
Tutton, R., & Prainsack, B. (2011) · Sociology of Health & Illness · doi:10.1111/j.1467-9566.2011.01348.x · Cited by 90
Direct-to-consumer genomics on the scales of autonomy
Vayena, E. (2015) · Journal of Medical Ethics · doi:10.1136/medethics-2014-102026 · Cited by 62
Wilde, A., Chan, H.-N., Rahman, B., Meiser, B., Mitchell, P. B., Schofield, P. R., & Green, M. J. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.01.014 · Cited by 55
Metadata
- Authors
- Giovanni, M. A., Fickie, M. R., Lehmann, L. S., Green, R. C., Meckley, L. M., Veenstra, D., & Murray, M. F.
- Venue
- Genetic Testing and Molecular Biomarkers
- Publisher
- SAGE Publications
- Published
- 2010-12
- Volume
- 14
- Issue
- 6
- Pages
- 817-819
- ISSN
- 1945-0257 (ISSN-L)
- 1945-0265
- OpenAlex
- W2079019815
- Cited by
- 59
- References
- 1
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.